Comparative Pharmacology
Head-to-head clinical analysis: LOREEV XR versus VALIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOREEV XR versus VALIUM.
LOREEV XR vs VALIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levetiracetam is a racetam anticonvulsant that binds to synaptic vesicle glycoprotein 2A (SV2A), reducing neurotransmitter release and neuronal excitability. It also inhibits N-type calcium channels and modulates GABAergic and glutamatergic transmission.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
50 mg orally once daily, preferably in the evening. Maximum dose 100 mg/day.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in healthy adults; prolonged in renal impairment (up to 16 hours in severe impairment).
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Renal excretion of unchanged drug accounts for approximately 70% of elimination; fecal excretion accounts for approximately 30%, primarily as metabolites.
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Category C
Category C
Benzodiazepine
Benzodiazepine